Clinical trial NCT01294982: Study of AOBO-001 for Overactive Bladder With Urge Urinary Incontinence and Frequency
Official title: Phase II, Randomized, Double-blind, Placebo-controlled Trial of the AOBO-001 for the Treatment of Overactive Bladder With Symptoms of Urge Urinary Incontinence and Frequency
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Overactive Bladder
Keywords: OAB
Over Active Bladder
overactive bladder
Urinary Urge Incontinence
Urinary Incontinence
Lead sponsor: American Oriental Bioengineering, Inc.
Sponsor class: INDUSTRY
First posted: 2011-02-14
Enrollment: 66
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the safety, tolerability, and effectiveness of the study product, AOBO-001, when taken by adults with symptoms of overactive bladder. AOBO-001, is experimental, which means that the U. S. Food and Drug Administration (FDA) has not yet approved it for use. AOBO-001 has been approved in China as a prescription drug product to treat bedwetting in children. AOBO-001 is also approved in Hong Kong as a dietary supplement to improve quality of life for people with urinary incontinence. AOBO-001 is a botanical (from a plant) product. It is prepared from the seeds of Xanthoceras sorbifolia bunge plant, which is a flowering tree grown in Northern China. Approximately 60 subjects who are 18 years of age and older are expected to participate in this study at up to 8 investigational sites. Each subject will complete 6 visits to the study site over a 14-week period. Subjects will consume 8 capsules of the assigned test product twice daily (that is, 16 capsules daily). Capsules will be taken with at least 6 ounces of water approximately 30 minutes before breakfast and 30 minutes before dinner. If a subject qualifies, he/she will be randomly (by chance) assigned to one of three study treatment groups. Subjects in one group will consume capsules containing a daily dose of 3.2 grams of AOBO-001; a second group will consume capsules containing a daily dose of 6.4 grams of AOBO-001; and a third group will consume capsules containing a placebo (no active ingredients). Subjects will have a 2 in 3 chance of being assigned to an active study treatment group. Neither the subject nor the study doctor will know to which study treatment group the subject has been assigned, but this information is available in case of a medical emergency. There will be a time during the study dosing schedule when all subjects will consume capsules containing a placebo (no active ingredients). Subjects will not be told when they are receiving the placebo.

Detailed description: This randomized, double-blind, placebo-controlled Phase 2 clinical trial will evaluate the safety and efficacy of AOBO-001 in adults with overactive bladder. The primary objective of this study is to evaluate the efficacy of AOBO 001 compared with placebo on the basis of the change from baseline in average number of micturition episodes per 24 hours from the 3-day diaries and average number of urge urinary incontinence episodes per 24 hours from the 3 day diaries during the double-blind treatment period in adult patients with OAB. Secondary efficacy objectives are to evaluate the efficacy of AOBO-001 compared with placebo on the basis of the number and severity of urgency episodes by using the Patient's Perception of Intensity of Urgency Scale (PPIUS), nocturia episodes, volume voided per micturition, and Patient Perception of Bladder Condition (PPBC) global assessment measure. An additional secondary objective is to evaluate the safety and tolerability of AOBO-001 compared with placebo.

Eligible patients will be randomized in equal proportions to double-blind treatment with AOBO 001 1.6 g twice daily (3.2 g daily), AOBO-001 3.2 g twice daily (6.4 g daily) or placebo capsules twice daily.

Efficacy assessments include urinary diary assessments, including the number of micturitions (daytime, nighttime), number of urge incontinence episodes, number/grading of urgency episodes (Patient's Perception of Intensity of Urgency Scale or PPIUS), and volume of voided urine; and Patient Perception of Bladder Condition (PPBC) questionnaire. Safety assessments include post-void residual urine volume measured by bladder scan; vital signs, 12-lead ECGs, complete or brief physical examinations, clinical laboratory safety tests, and treatment-emergent adverse events.

Eligibility criteria: Inclusion Criteria:

1. Patient is male or female aged 18 years or older and provides written informed consent;
2. Patient has had symptoms of OAB, including urinary frequency, urgency or urge incontinence, for at least 3 months prior to the screening visit;
3. Patient is compliant with completing 3 consecutive days of the urinary diary each week and at least 85% compliant with taking placebo capsules during the 2-week placebo run-in period;
4. Patient experiences an average micturition frequency of ≥8 times per a 24-hour period based on the 24-hour average of 3 consecutive days of urinary diary data during the last week of the 2-week placebo run-in period;
5. Patient has had at least 4 episodes of incontinence over a 3 consecutive day urinary diary period during the 2-week placebo run-in period; and
6. Patient has had at least 4 episodes of urgency (PPIUS Grade 3 or 4) with or without incontinence over a 3 consecutive day urinary diary period during the 2-week placebo run-in period.

Exclusion Criteria:

1. Patients with known allergy to plants of Sapindaceae family, including maple syrup, litchi (Litchi chinensis), rambutan (Nephelium lappaceum), longan (Euphoria longana), ackee (Blighia sapida) and Spanish Lemon (Melicoccus bijugus).
2. Pregnant women or women who intend to become pregnant during the study or women of childbearing potential who are sexually active and practicing an unreliable method of birth control or will be lactating during the study. Reliable contraceptive methods are intra-uterine devices, double-barrier method (condom with spermicide), contraceptive pills of combination type, hormonal implants and injectable or patch contraceptives;
3. Clinically significant outflow obstruction (at the discretion of the investigator);
4. Significant stress incontinence or mixed stress/urge incontinence where stress is the predominant factor, as determined by the investigator;
5. Patient with indwelling catheters or practicing intermittent self-catheterization;
6. Evidence of a symptomatic urinary tract infection, chronic inflammation such as interstitial cystitis, bladder stones, previous pelvic radiation therapy or previous or current malignant disease of the pelvic organs;
7. Non-drug OAB treatment such as bladder-training, biofeedback and pelvic floor exercises are permissible if established at least 4 weeks prior to study start and intended to be continued throughout the study; electrostimulation therapy is not permissible at any time;
8. Use of drugs intended to treat urinary incontinence, such as darifenacin (Enablex), fesoterodine (Toviaz), oxybutynin (Ditropan, Ditropan XL, Oxytrol), solifenacin (Vesicare), tolterodine (Detrol, Detrol LA), and trospium (Sanctura, Sanctura XR);
9. Any clinically significant condition, which in the opinion of the investigator makes the patient unsuitable for the trial, including without limitation, major cardiovascular or cerebrovascular event (e.g., myocardial infarction, stroke, unstable angina, transient ischemic attacks) within the past year, major neurological disorders (e.g., paralysis or neuropathies, multiple sclerosis), major psychiatric diseases (e.g., major depression, generalized anxiety, psychosis), unstable or poorly controlled chronic diseases (e.g., uncontrolled moderate to severe hypertension or poorly controlled diabetes mellitus), and moderate to severe renal or hepatic disease;
10. Participation in any clinical trial within 30 days prior to randomization;
11. Women who suffer from undiagnosed vaginal bleeding;
12. Employees of AOBO, third parties associated with the study, or the study site; and
13. Patient who did not complete the urinary diary (3 consecutive days of valid urinary diary data each week) and did not take placebo run-in study medication (at least 85% compliance) according to the instructions during the placebo run-in period.

Primary outcomes:
measure: Change in average number of micturitions per 24 hours from 3-day urinary diaries compared to baseline
timeFrame: Endpoint (up to 12 weeks of double-blind treatment)
measure: Change in average number of urge incontinence episodes per 24 hours from 3-day urinary diaries compared to baseline
timeFrame: Endpoint (up to 12 weeks of double-blind treatment)
Secondary outcomes:
measure: Change in volume voided per micturition compared to baseline
timeFrame: Endpoint (up to 12 weeks of double-blind treatment)
measure: Change in intensity of urgency episodes compared to baseline
timeFrame: Endpoint (up to 12 weeks of double-blind treatment)
measure: Change in daytime and sleeptime micturitions compared to baseline
timeFrame: Endpoint (up to 12 weeks of double-blind treatment)
measure: Change in weekly urge incontinence episodes compared to baseline
timeFrame: Endpoint (up to 12 weeks of double-blind treatment)
measure: Change in PPBC score compared to baseline
timeFrame: Endpoint (up to 12 weeks of double-blind treatment)
measure: Number of Participants with Adverse Events as a Measure of Safety and Tolerability
timeFrame: During double-blind treatment phase
Other outcomes:
Locations:
city: Mobile
country: United States
facility: Coastal Clinical Research
state: Alabama
city: West Palm Beach
country: United States
facility: Palm Beach Research Center
state: Florida
city: Newton
country: United States
facility: Heartland Research Associate, LLC
state: Kansas
city: Greenbelt
country: United States
facility: Myron I. Murdock M.D. LLC
state: Maryland
city: Endwell
country: United States
facility: Regional Clinical Research, Inc
state: New York
Study officials:
affiliation: American Oriental Bioengineering, Inc.
name: Tom Du, MD, PhD
role: STUDY_DIRECTOR
References: